Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 5/20 | 0.43 |
| ▸ | CNR1 | P21554 | 3/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KDM5A | P29375 | 1/20 | 0.38 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3343275 | 0.75 | CNR2 (0.65) | CNR2CNR1ALDH1A1MAPTKMT2A | |
| SCHEMBL3451768 | 0.72 | ALDH1A1 (0.38) | CNR2CNR1ALDH1A1SMN1; SMN2KDM4E | |
| Pyromellitic Acid SCHEMBL11649085 | 0.69 | ALDH1A1 (0.58) | GLAALDH1A1MAPTKMT2AKDM4E | |
| SCHEMBL3344524 | 0.69 | KMT2A (0.35) | ALDH1A1MAPTKMT2ASMN1; SMN2KDM4E | |
| SCHEMBL4250096 | 0.68 | ALDH1A1 (0.52) | ALDH1A1MAPTKMT2ASMN1; SMN2KDM4E | |
| SCHEMBL6310590 | 0.68 | CNR2 (0.62) | CNR2CNR1ALDH1A1MAPTKMT2A | |
| SCHEMBL12168494 | 0.67 | CNR1 (0.70) | CNR2CNR1 | |
| SCHEMBL3450024 | 0.67 | SMN1; SMN2 (0.47) | CNR2CNR1GLAALDH1A1MAPT | |
| SCHEMBL3345829 | 0.66 | ALDH1A1 (0.42) | GLAALDH1A1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL3449727 | 0.66 | SMN1; SMN2 (0.55) | CNR2CNR1GLAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| WO-2010038081-A2 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | CNR2 517/4885CNR1 653/4885GLA 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.